Pricing Log in Create free account
Saturday 17 October 2026 Export NPCE’s income statement to Excel — free account

NeuroPace, Inc.

NPCE Healthcare Medical Devices

In the quarter to June 2026, revenue grew 17.1%, EPS grew 30.8%, free cash flow fell 78.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

12.24 0.54 −4.23%
Market cap
$438.7M
P/E
0.0×
Fwd P/E
−27.1×
Dividend yield
—
F-score
5/9
Altman Z
−2.52
Beneish M
−2.88
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.40
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — 1 — — — — — — — — — —
Insider Ownership 21.42%

Capital & Financial Ratios $m

Market Cap 438.66
Revenue 102.86
Net Income (19.11)
Free Cash Flow (11.61)
Net Debt 7.32
Current Ratio 4.94 (at or above 1.5: strong)
Debt/Equity 4.97 (above 2: weak)
P/E ratio 0.00
Fwd P/E (27.10) (negative: loss-making)
P/S ratio 4.06
P/B ratio 35.13 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 16.28% (at or above 15%: strong)
Next Y EPS Growth 47.35% (at or above 15%: strong)
Next Y revenue growth 0.31%
Next 5Y EPS Growth 45.68% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.2×, against a ten-year median of 3.8×; over the ten years it ranged from 0.2× in 2022 to 7.2× in 2021.
P/S against its own 10 years 55.69%
10-year low 10-year high
P/B against its own 10 years 85.80%
10-year low 10-year high
EV/Sales against its own 10 years 59.90%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 66 53 61 52
Receivables 12 13 15 15
Inventory 11 13 17 18
Other — — — —
93 81 94 86
2023 2024 2025 Q'26
Payables 2 3 2 4
ST’ Debt — — — —
Other — — — —
16 15 18 17

Compound Annual Growth %

10y 5y 3y
Sales — 19.44% 29.99%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% (18.21%)

Revenue $m

Mar Jun Sep Dec Year
’26 22 23 — — —
’25 23 20 27 31 100
’24 18 19 21 21 80
’23 14 17 16 18 65
’22 11 10 11 13 46
’21 11 13 10 11 45
’20 10 8 13 11 41
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (4) — — —
’25 (7) (2) (2) 1 (11)
’24 (8) (4) (2) (5) (18)
’23 (10) (4) (2) (3) (20)
’22 (11) (11) (7) (8) (37)
’21 (6) (6) (4) (8) (25)
’20 (7) (3) (5) (6) (22)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (4) — — —
’25 (8) (2) (2) 0 (11)
’24 (8) (4) (2) (5) (18)
’23 (10) (4) (2) (3) (20)
’22 (12) (11) (7) (8) (37)
’21 (6) (6) (5) (8) (25)
’20 (7) (3) (5) (6) (22)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.20) (0.18) — — —
’25 (0.21) (0.26) (0.11) (0.08) (0.66)
’24 (0.32) (0.26) (0.19) (0.18) (0.93)
’23 (0.41) (0.36) (0.28) (0.23) (1.27)
’22 (0.47) (0.52) (0.48) (0.45) (1.91)
’21 (32.73) (0.48) (0.34) (0.44) (2.17)
’20 (33.32) (43.53) (20.43) (21.16) (118.43)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 8.29 1.22 1.38 5.45 7.56

Analyst estimates 2026–2028

Powerpack
High — — — — — 27.38 12.06 10.32 18.15 18.98
People
People Employees — — — — 152 166 167 171 184 209
Revenue/emp, $m — — — 0.00 0.27 0.27 0.27 0.38 0.43 0.48
Income, $m
Income, $m Revenue — — — 37 41 45 46 65 80 100
Gross margin, % — — — 71.58 73.59 74.00 71.38 73.56 73.94 77.23
EBT — — — (30) (24) (36) (47) (33) (27) (21)
EBT margin, % — — — (81.07) (59.02) (79.85) (103.43) (50.38) (33.97) (21.47)
Net income — 0 — (30) (24) (36) (47) (33) (27) (21)
Depreciation — — — 3 4 1 1 0 2 2
Per share, $
Per share, $ Revenue — — — 183.12 200.67 2.72 1.85 2.53 2.74 3.06
Earnings — — — (148.44) (118.43) (2.17) (1.91) (1.27) (0.93) (0.66)
Cash flow — — — (123.95) (105.41) (1.48) (1.50) (0.76) (0.62) (0.34)
Capex — — — (2.30) (0.30) (0.02) (0.02) (0.01) (0.01) (0.01)
Free cash flow — — — (126.25) (105.71) (1.50) (1.52) (0.77) (0.63) (0.35)
Book value — — — (640.66) (721.13) 4.43 1.41 0.80 0.28 0.58
Shares, m — — — 0 0 17 25 26 29 33
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 0.16 0.16 3.71 0.78 3.86 4.08 5.05
P/B — — — 0.00 0.00 2.28 1.02 12.24 40.67 26.55
EV/Sales — — — 0.69 0.69 2.33 0.32 3.77 4.21 5.07
EV/FCF — — — (1.39) (1.39) (4.22) (0.39) (12.42) (18.42) (44.69)
Cash, $m
Cash, $m Operating cash flow — — — (25) (22) (25) (37) (20) (18) (11)
Capex — — — 0 0 0 (1) 0 0 0
Free cash flow — — — (25) (22) (25) (37) (20) (18) (11)
Balance, $m
Balance, $m Working capital — — — (55) 45 124 87 76 66 76
Total debt — — — 44 53 50 53 57 60 59
Net debt — — — 39 15 (66) (24) (9) 7 (2)
Shareholders’ equity — — — (129) (148) 74 35 21 8 19
Returns, %
Returns, % ROA — — — (284.17) (63.02) (38.08) (38.02) (29.72) (26.83) (21.44)
ROIC — — — 0.00 0.00 (191.03) (247.99) (152.27) (91.62) (60.58)
ROE — — — 21.63 17.52 97.08 (86.96) (118.91) (189.35) (158.74)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

NeuroPace, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
DCTH Delcath Systems, Inc. $513.9M 1,408× — (loss-making) +20.60% (above 0%: growing) −12.50% (below 0%: shrinking) −24.45% (below 0%: shrinking) 89.75% 8.22% Compare
MASS 908 Devices Inc. $491.5M — (loss-making) — (loss-making) +23.31% (above 0%: growing) n/m +150.95% (above 0%: growing) 51.90% (79.69%) Compare
SGHT Sight Sciences, Inc. $484.8M — (loss-making) — (loss-making) +19.55% (above 0%: growing) n/m +26.71% (above 0%: growing) 91.39% (16.62%) Compare
BWAY Brainsway Ltd. Sponsored ADR $475.8M 24.8× — (loss-making) +35.43% (above 0%: growing) +40.00% (above 0%: growing) −51.68% (below 0%: shrinking) 74.62% 13.98% Compare
CERS Cerus Corporation $455.5M — (loss-making) — (loss-making) +5.28% (above 0%: growing) n/m −20.90% (below 0%: shrinking) 55.91% (2.94%) Compare
NPCE NeuroPace, Inc. $438.7M — (loss-making) — (loss-making) +17.05% (above 0%: growing) n/m −78.70% (below 0%: shrinking) 82.83% (22.53%)
SENS Senseonics Holdings, Inc. $435.2M — (loss-making) — (loss-making) +117.82% (above 0%: growing) n/m −223.24% (below 0%: shrinking) 59.10% (248.48%) Compare
OFIX ORTHOFIX MEDICAL INC. $390.6M — (loss-making) — (loss-making) +3.85% (above 0%: growing) n/m −516.58% (below 0%: shrinking) 70.97% (3.86%) Compare
SI Shoulder Innovations, Inc. $382.4M — (loss-making) — (loss-making) +55.95% (above 0%: growing) n/m −52.42% (below 0%: shrinking) 78.26% (58.43%) Compare
Median of peers $465.6M — — +21.96% — −38.07% 72.80% (10.24%)

All 149 Medical Devices stocks →

NeuroPace, Inc. (NPCE) key facts

  • Concern: NeuroPace, Inc. reported a net loss of $21.5 million, or a loss of $0.66 per share, for fiscal 2025.
  • NeuroPace, Inc. (NPCE) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, NPCE traded at $12.24, a market capitalization of $438.7 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.1× sales.
  • Return on equity was −158.7% and debt-to-equity 4.97.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −2.52 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

NeuroPace, Inc. (NPCE) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/NPCE · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com